Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,010.10 | 117.10 | -1.28% |
CAC 40 | 7,719.71 | 65.46 | 0.86% |
DAX 40 | 23,594.80 | 107.47 | 0.46% |
Dow JONES (US) | 45,013.81 | 282.00 | -0.62% |
FTSE 100 | 9,177.99 | 61.30 | 0.67% |
HKSE | 25,343.43 | 153.12 | -0.60% |
NASDAQ | 21,438.67 | 159.04 | 0.75% |
Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
S&P 500 | 6,423.74 | 8.20 | 0.13% |
S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
SSE Composite Index | 3,813.56 | 44.58 | -1.16% |